Please assess the completion status of the following clinical trial:

Trial Title: Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age≥18 and ≤ 80;~* Suspected lage vessel occlusion of acute anterior circulation occlusion; i.e. either the ICA or the M1-segment of the MCA;~* Acute ischemic stroke where patient is ineligible for intravenous thrombolytic treatment or the treatment is contraindicated, or where patient has received intravenous thrombolytic therapy without recanalization;~* Patient treatable within 6 hours of symptom onset;or it has been more than 6 hours but not more than 24 hours,and imaging confirmed the existence of ischemic penumbra;~* NIHSS score≥6分~* Alberta Stroke Program Early CT score (ASPECTS) of 7-10 on non-contrast CT;~* Informed consent obtained;~Exclusion Criteria:~* Rapid improvement in neurological status to an NIHSS \< 6 or evidence of vessel recanalization prior to randomization;~* Seizures at stroke onset;~* Intracranial hemorrhage;~* Systolic pressure greater than 185 mm Hg or diastolic pressure greater than 110 mm Hg, or aggressive treatment intravenous medication)necessary to reduce blood pressure to these limits;~* Symptoms rapidly improving;~* Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal;~* Platelet count of less than 100,000 per cubic millimeter;~* CT showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere);~* severe hepatic or renal dysfunction;~* active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;~* \>3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2)﹥95% as per current stroke management guidelines;~* medically unstable;~* inability to obtain informed consent;~* Life expectancy\<90 days;~* Pregnant or breast-feeding women;~* Unwilling to be followed up or poor compliance for treatment;~* Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial;~* Evidence of intracranial tumor;~* Baseline blood glucose of \< 50 mg/dL (2.78 mmol) or \> 400 mg/dL (22.20 mmol);

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NBO group (Type: EXPERIMENTAL): Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
- Control group (Type: NO_INTERVENTION): The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).